Table 2.

Adherence to PEG-IFN among treated HCV and HCV/HIV infected participants with recently acquired HCV infection (n=109)

	Overall (n=109)	HCV (n=74)	HCV/HIV (n=35)
PEG-IFN 80/80 adherence, n (%)	89 (82)	57 (77)	32 (91)
Mean on-treatment PEG-IFN adherence, (%)	99.4	98.0	99.5
Missed doses of PEG-IFN, n (%)
No missed doses	94 (86)	63 (85)	31 (89)
1 missed dose	10 (9)	6 (8)	4 (11)
2-5 missed doses	5 (5)	5 (7)	0 (0)
Number of weeks of PEG-IFN therapy, n (%)
24 weeks	76 (70)	50 (68)	26 (74)
20 to 23 weeks	7 (6)	3 (4)	4 (11)
10 to 19 weeks	15 (14)	11 (15)	4 (11)
0 to 9 weeks	11 (10)	10 (14)	1 (3)
Weeks on PEG-IFN therapy
Mean, n (SD)	20 (6.9)	19.6 (7.7)	22.1 (4.4)
Median, n (IQR)	24 (20-24)	24 (18-24)	24 (22-24)
PEG-IFN dose-modification	5 (5)	4 (5)	1 (3)

SD=standard deviation; IQR=interquartile range.